QuantBioRes

Curated by Signal

Developer of small molecule therapeutics for COVID-19

Overview

Developer of small molecule therapeutics for COVID-19. It offers a peptide-based drug that obstructs the Covid-19 virus from infecting the human cell. It has a Resonant Recognition Model that enables the characteristic frequencies which are electromagnetic in nature to be identified for each biological function or interaction.

Key facts

Founded: 2020
Headquarters: Copenhagen, Denmark
Stage: Sign up to view
Industry: Life Sciences Technology

Contact

Primary office: Sign up to view
Email: Sign up to view
Phone: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Aida Oncology
Developer of machine-optimized algorithms to predict drugs for cancer patients
Life Sciences TechnologyCopenhagen, Denmark
ReVac Aps
Provider of a transfer and rehabilitation device for disabled people
Life Sciences TechnologyKorsor, Denmark
Diramo
Developer of continuous blood glucose monitoring devices for intensive care units
Life Sciences TechnologySonderborg, Denmark

About QuantBioRes

What does QuantBioRes do?

Developer of small molecule therapeutics for COVID-19.

Where is QuantBioRes headquartered?

QuantBioRes is headquartered in Copenhagen, Denmark.

When was QuantBioRes founded?

QuantBioRes was founded in 2020.

Which sector is QuantBioRes in?

QuantBioRes operates in Life Sciences Technology.

Who are QuantBioRes's competitors?

Companies similar to QuantBioRes include Aida Oncology, ReVac Aps, and Diramo.